Clinical Data Viridian reports positive results from elegrobart phase 3 trial PharmaTimesCompany says treatment shows strong efficacy and convenient dosing profileClinical DataRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Company says treatment shows strong efficacy and convenient dosing profile Clinical DataRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2DNext: FDA approves new high dose Spinraza regimen for SMA Related Stories Clinical Data Parsortix study shows promise for ADC target detection pharminent August 3, 2026 Clinical Data Novo setback casts doubt on a new way to treat heart disease pharminent July 31, 2026 Clinical Data Altimmune rises as GLP-1/GIP drug curbs heavy drinking in mid-stage study pharminent July 28, 2026
